Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


New Amedeo service:

Amedeo COVID-19 (formerly 2019-nCoV)

Weekly publication summary


  Leukemia

  Free Subscription


Articles published in Leuk Res

Retrieve available abstracts of 302 articles:
HTML format
Text format



Single Articles


    February 2020
  1. QASRAWI A, Gomes V, Chacko CA, Mansour A, et al
    Acute undifferentiated leukemia: data on incidence and outcomes from a large population-based database.
    Leuk Res. 2020;89:106301.
    PubMed     Text format     Abstract available


  2. GORDON MJ, Sitlinger A, Salous T, Alqahtani H, et al
    A simplified prognostic index for chronic lymphocytic leukemia treated with ibrutinib: Results from a multicenter retrospective cohort study.
    Leuk Res. 2020;89:106302.
    PubMed     Text format    


    January 2020
  3. SHALLIS RM, Patel TH, Podoltsev NA, Xu ML, et al
    Disseminated, yet dissembled: Rare infections behind the veil of classical hairy cell leukemia.
    Leuk Res. 2020;90:106315.
    PubMed     Text format    


  4. GAUT D, Burkenroad A, Duong T, Feammelli J, et al
    Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: A single institution experience.
    Leuk Res. 2020;90:106314.
    PubMed     Text format     Abstract available


  5. SCHECKEL CJ, Meyer M, Betcher JA, Al-Kali A, et al
    Efficacy of mitoxantrone-based salvage therapies in relapsed or refractory acute myeloid leukemia in the Mayo Clinic Cancer Center: Analysis of survival after 'CLAG-M' vs. 'MEC'.
    Leuk Res. 2020;90:106300.
    PubMed     Text format     Abstract available


  6. ZHU Y, Gao Q, Hu J, Liu X, et al
    Clinical features and treatment outcomes in patients with T-cell large granular lymphocytic leukemia: A single-institution experience.
    Leuk Res. 2020;90:106299.
    PubMed     Text format     Abstract available


  7. SAYGIN C, Grieselhuber N, Blachly J, Byrd JC, et al
    Outcomes of the cyclophosphamide, vincristine, prednisone (CVP) +/- rituximab (R-CVP) regimen in older patients with newly diagnosed Ph- acute lymphoblastic leukemia.
    Leuk Res. 2020;89:106297.
    PubMed     Text format    


  8. SEIPEL K, Messerli C, Wiedemann G, Bacher U, et al
    MN1, FOXP1 and hsa-miR-181a-5p as prognostic markers in acute myeloid leukemia patients treated with intensive induction chemotherapy and autologous stem cell transplantation.
    Leuk Res. 2020;89:106296.
    PubMed     Text format     Abstract available


  9. HILLIS CM, Jackson Chornenki NL, Bence-Bruckler I, Busque L, et al
    The predictive value of intracellular imatinib levels in newly diagnosed chronic myeloid leukemia.
    Leuk Res. 2020;88:106285.
    PubMed     Text format    


    December 2019
  10. BODROG A, Zhang B, Liu L, Casulo C, et al
    A case of Burkitt Leukemia: Revisiting the prognostic value of lactate dehydrogenase.
    Leuk Res. 2019;89:106295.
    PubMed     Text format    


  11. JASKOVA Z, Pavlova S, Malcikova J, Brychtova Y, et al
    PRIMA-1(MET) cytotoxic effect correlates with p53 protein reduction in TP53-mutated chronic lymphocytic leukemia cells.
    Leuk Res. 2019;89:106288.
    PubMed     Text format     Abstract available


    November 2019
  12. JABBOUR E, Gokbuget N, Advani A, Stelljes M, et al
    Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.
    Leuk Res. 2019;88:106283.
    PubMed     Text format     Abstract available


  13. URESHINO H, Shindo T, Kimura S
    Role of cancer immunology in chronic myelogenous leukemia.
    Leuk Res. 2019;88:106273.
    PubMed     Text format     Abstract available


  14. ZENG H, Wu H, Yan M, Tang L, et al
    Characterization of a 4 lncRNAs-based prognostic risk scoring system in adults with acute myeloid leukemia.
    Leuk Res. 2019;88:106261.
    PubMed     Text format     Abstract available


  15. QUENTMEIER H, Pommerenke C, Dirks WG, Fahnrich S, et al
    DNMT3A R882H mutation in acute myeloid leukemia cell line SET-2.
    Leuk Res. 2019;88:106270.
    PubMed     Text format    


  16. YANO Y, Schiffman C, Grigoryan H, Hayes J, et al
    Untargeted adductomics of newborn dried blood spots identifies modifications to human serum albumin associated with childhood leukemia.
    Leuk Res. 2019;88:106268.
    PubMed     Text format     Abstract available


    October 2019
  17. WANG G, Li X, Song L, Pan H, et al
    Long noncoding RNA MIAT promotes the progression of acute myeloid leukemia by negatively regulating miR-495.
    Leuk Res. 2019;87:106265.
    PubMed     Text format     Abstract available


  18. JEONG D, Lee DS, Kim N, Choi S, et al
    Corrigendum to "Prevalence of germline predisposition gene mutations in pediatric acute myeloid leukemia: Genetic background of pediatric AML" [Leuk. Res. 85 (2019) (October) 106210].
    Leuk Res. 2019 Oct 28:106249. doi: 10.1016/j.leukres.2019.106249.
    PubMed     Text format    


  19. MIYAMURA T, Kudo K, Tabuchi K, Ishida H, et al
    Hematopoietic stem cell transplantation for pediatric acute myeloid leukemia patients with KMT2A rearrangement; A nationwide retrospective analysis in Japan.
    Leuk Res. 2019;87:106263.
    PubMed     Text format     Abstract available


  20. WILLIS C, Menon J, Unni S, Au T, et al
    Clinical and economic analysis of patients with acute myeloid leukemia by FLT3 status and midostaurin use at a Comprehensive Cancer Center.
    Leuk Res. 2019;87:106262.
    PubMed     Text format     Abstract available


  21. LIMVORAPITAK W, Owattanapanich W, Utchariyaprasit E, Niparuck P, et al
    Better survivals in adolescent and Young adults, compared to adults with acute lymphoblastic leukemia - A multicenter prospective registry in Thai population.
    Leuk Res. 2019;87:106235.
    PubMed     Text format     Abstract available


  22. KATSARAKI K, Artemaki PI, Papageorgiou SG, Pappa V, et al
    Identification of a novel, internal tRNA-derived RNA fragment as a new prognostic and screening biomarker in chronic lymphocytic leukemia, using an innovative quantitative real-time PCR assay.
    Leuk Res. 2019;87:106234.
    PubMed     Text format     Abstract available


  23. PREZZO A, Cavaliere FM, Bilotta C, Pentimalli TM, et al
    Ibrutinib-based therapy impaired neutrophils microbicidal activity in patients with chronic lymphocytic leukemia during the early phases of treatment.
    Leuk Res. 2019;87:106233.
    PubMed     Text format     Abstract available


    September 2019
  24. GATINEAU-SAILLIANT S, Glisovic S, Gagne V, Laverdiere C, et al
    Impact of DARC, GSDMA and CXCL2 polymorphisms on induction toxicity in children with acute lymphoblastic leukemia: A complementary study.
    Leuk Res. 2019;86:106228.
    PubMed     Text format    


  25. NAKAMURA R, Gendzekhadze K, Palmer J, Tsai NC, et al
    Influence of donor KIR genotypes on reduced relapse risk in acute myelogenous leukemia after hematopoietic stem cell transplantation in patients with CMV reactivation.
    Leuk Res. 2019;87:106230.
    PubMed     Text format     Abstract available


  26. LIU M, Liao H, Chen Y, Lin Z, et al
    Treatment of human T-cell acute lymphoblastic leukemia cells with CFTR inhibitor CFTRinh-172.
    Leuk Res. 2019;86:106225.
    PubMed     Text format     Abstract available


  27. MARCOLIN R, Guolo F, Minetto P, Clavio M, et al
    A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia.
    Leuk Res. 2019;86:106223.
    PubMed     Text format     Abstract available


  28. BESTACH Y, Toloza MJ, Ferri C, Larripa I, et al
    The dynamic of TNF and IL6 gene expression in chronic myeloid leukemia patients reveals early responders to imatinib.
    Leuk Res. 2019;86:106221.
    PubMed     Text format    


    August 2019
  29. YANG L, Kost SEF, Beiggi S, Zhang Y, et al
    Buccal cell telomere length is not a useful marker for comorbidities in chronic lymphocytic leukemia.
    Leuk Res. 2019;86:106220.
    PubMed     Text format    


  30. KRUZOVA L, Schneiderova P, Holzerova M, Vatolikova M, et al
    Complex karyotype as a predictor of high-risk chronic lymphocytic leukemia: A single center experience over 12 years.
    Leuk Res. 2019;85:106218.
    PubMed     Text format     Abstract available


  31. JEONG D, Lee DS, Kim N, Choi S, et al
    Prevalence of germline predisposition gene mutations in pediatric acute myeloid leukemia: Genetic background of pediatric AML.
    Leuk Res. 2019;85:106210.
    PubMed     Text format    


  32. STRATMANN J, van Kann E, Rummelt C, Koschade S, et al
    Low-dose melphalan in elderly patients with relapsed or refractory acute myeloid leukemia: A well-tolerated and effective treatment after hypomethylating-agent failure.
    Leuk Res. 2019;85:106192.
    PubMed     Text format     Abstract available


  33. SHANG J, Chen WM, Liu S, Wang ZH, et al
    CircPAN3 contributes to drug resistance in acute myeloid leukemia through regulation of autophagy.
    Leuk Res. 2019;85:106198.
    PubMed     Text format     Abstract available


  34. DEANGELO DJ, Walker AR, Schlenk RF, Sierra J, et al
    Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia.
    Leuk Res. 2019;85:106197.
    PubMed     Text format     Abstract available


    July 2019
  35. OTOUKESH S, Salhotra A, Marcucci G, Forman SJ, et al
    The feasibility of venetoclax and decitabine in therapy-related acute myeloid leukemia with concurrent advanced non-hematological malignancies.
    Leuk Res. 2019;84:106196.
    PubMed     Text format    


  36. YUN S, Sharma R, Chan O, Vincelette ND, et al
    Prognostic significance of MYC oncoprotein expression on survival outcome in patients with acute myeloid leukemia with myelodysplasia related changes (AML-MRC).
    Leuk Res. 2019;84:106194.
    PubMed     Text format     Abstract available


  37. HUANG SJ, Chan J, Bruyere H, Allan LL, et al
    Chronic lymphocytic leukemia patients with HLA-B27 referred for allogeneic hematopoietic stem cell transplantation do not have worse outcomes: Results of a population-based case series analysis in British Columbia, Canada.
    Leuk Res. 2019;84:106193.
    PubMed     Text format     Abstract available


  38. HWANG SM, Kim SM, Nam Y, Kim J, et al
    Targeted sequencing aids in identifying clonality in chronic myelomonocytic leukemia.
    Leuk Res. 2019;84:106190.
    PubMed     Text format     Abstract available


  39. VIJAY V, Miller R, Vue GS, Pezeshkian MB, et al
    Interleukin-8 blockade prevents activated endothelial cell mediated proliferation and chemoresistance of acute myeloid leukemia.
    Leuk Res. 2019;84:106180.
    PubMed     Text format     Abstract available


    June 2019
  40. JAIN P, Gu J, Kanagal-Shamanna R, Tang Z, et al
    Clinical implications of cytogenetic heterogeneity in Philadelphia chromosome positive (Ph++) adult B cell acute lymPh+oblastic leukemia following tyrosine kinase inhibitors and chemotherapy regimens.
    Leuk Res. 2019;84:106176.
    PubMed     Text format     Abstract available


  41. HUTMACHER C, Volta L, Rinaldi F, Murer P, et al
    Development of a novel fully-human anti-CD123 antibody to target acute myeloid leukemia.
    Leuk Res. 2019;84:106178.
    PubMed     Text format     Abstract available


  42. MITRAKOS A, Kattamis A, Katsibardi K, Papadhimitriou S, et al
    High resolution Chromosomal Microarray Analysis (CMA) enhances the genetic profile of pediatric B-cell Acute Lymphoblastic Leukemia patients.
    Leuk Res. 2019;83:106177.
    PubMed     Text format     Abstract available


  43. HAMBLEY BC, Norsworthy KJ, Jasem J, Zimmerman JW, et al
    Fibrinogen consumption and use of heparin are risk factors for delayed bleeding during acute promyelocytic leukemia induction.
    Leuk Res. 2019;83:106174.
    PubMed     Text format    


  44. D'ARENA G, Valvano L, Vitale C, Coscia M, et al
    CD200 and prognosis in chronic lymphocytic leukemia: Conflicting results.
    Leuk Res. 2019;83:106169.
    PubMed     Text format    


  45. LOU Y, Tong H, Yu W, Wei J, et al
    Efficacy and safety of early switching to an outpatient therapy model using oral arsenic plus retinoic acid based-regimen in newly diagnosed acute promyelocytic leukemia.
    Leuk Res. 2019;83:106168.
    PubMed     Text format     Abstract available


  46. DA SILVA WF, Neto AC, da Rosa LI, de Siqueira IA, et al
    Outcomes and second neoplasms in hairy cell leukemia: A retrospective cohort.
    Leuk Res. 2019;83:106165.
    PubMed     Text format     Abstract available


  47. FANG J, Zhang R, Wang H, Hong M, et al
    Corrigendum to 'Idarubicin-intensified BUCY2 conditioning regimen improved survival in high-risk acute myeloid, but not lymphocytic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: A retrospective comparative study.' [L
    Leuk Res. 2019;81:107.
    PubMed     Text format    


  48. CHIRON D, Jego G, Pellat-Deuceunynck C
    Corrigendum to 'Toll-like receptors Expression and involvement in Multiple Myeloma' [Leukemia Research 34 (2010)1545-1550].
    Leuk Res. 2019;81:106.
    PubMed     Text format    


    May 2019
  49. VASCONCELOS FC, Bonecker ST, de Souza PS, Scheiner MAM, et al
    Age, gender and efflux transporter activity influence imatinib efficacy in chronic myeloid leukemia patients.
    Leuk Res. 2019;82:33-35.
    PubMed     Text format    


  50. TADMOR T, Levy I, Herishanu Y, Goldschmidt N, et al
    Primary peg-filgrastim prophylaxis versus filgrastim given "on demand" for neutropenia during therapy with cladribine for hairy cell leukemia.
    Leuk Res. 2019;82:24-28.
    PubMed     Text format     Abstract available


  51. JAMY O, Sarmad R, Costa L
    Risk and outcomes of second malignant neoplasms in chronic myeloid leukemia survivors.
    Leuk Res. 2019;82:1-6.
    PubMed     Text format     Abstract available


  52. WANG YH, Liang JD, Sheng WH, Tien FM, et al
    Hepatitis B reactivation during treatment of tyrosine kinase inhibitors-Experience in 142 adult patients with chronic myeloid leukemia.
    Leuk Res. 2019;81:95-97.
    PubMed     Text format    


  53. ZINZANI PL, Rambaldi A, Gaidano G, Girmenia C, et al
    Infection control in patients treated for chronic lymphocytic leukemia with ibrutinib or idelalisib: recommendations from Italian society of hematology.
    Leuk Res. 2019;81:88-94.
    PubMed     Text format     Abstract available


  54. FLYNN KE, Mauro MJ, George G, Hinman A, et al
    Patients' perspectives on the definition of cure in chronic myeloid leukemia.
    Leuk Res. 2019;80:40-42.
    PubMed     Text format    


    April 2019
  55. SPUNAROVA M, Tom N, Pavlova S, Mraz M, et al
    Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
    Leuk Res. 2019;81:75-81.
    PubMed     Text format     Abstract available


  56. GERDS AT, Tauchi T, Ritchie E, Deininger M, et al
    Corrigendum to "Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib" [Leukemia Res. 79 (2019) 38-44].
    Leuk Res. 2019 Apr 24. pii: S0145-2126(19)30070.
    PubMed     Text format    


  57. STEVENS B, Winters A, Gutman JA, Fullerton A, et al
    Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis.
    Leuk Res. 2019;81:43-49.
    PubMed     Text format     Abstract available


  58. MOSHAVER B, Wouters RF, Kelder A, Ossenkoppele GJ, et al
    Relationship between CD34/CD38 and side population (SP) defined leukemia stem cell compartments in acute myeloid leukemia.
    Leuk Res. 2019;81:27-34.
    PubMed     Text format     Abstract available


  59. TURCSANYI P, Kriegova E, Kudelka M, Radvansky M, et al
    Improving risk-stratification of patients with chronic lymphocytic leukemia using multivariate patient similarity networks.
    Leuk Res. 2019;79:60-68.
    PubMed     Text format     Abstract available


  60. BAI Y, Shi M, Yang X, Zhang W, et al
    The value of FDP/FIB and D-dimer/FIB ratios in predicting high-risk APL-related thrombosis.
    Leuk Res. 2019;79:34-37.
    PubMed     Text format     Abstract available


  61. YUANXIN Y, Yanhong Z, Qin Z, Sishi T, et al
    Pak1 gene functioned differentially in different BCR-ABL subtypes in leukemiagenesis and treatment response through STAT5 pathway.
    Leuk Res. 2019;79:6-16.
    PubMed     Text format     Abstract available


    March 2019
  62. WANG S, Wang C, Wang W, Hao Q, et al
    High RASD1 transcript levels at diagnosis predicted poor survival in adult B-cell acute lymphoblastic leukemia patients.
    Leuk Res. 2019;80:26-32.
    PubMed     Text format     Abstract available


  63. GLEIXNER KV, Sadovnik I, Schneeweiss M, Eisenwort G, et al
    A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1(T315I) in Ph+ CML.
    Leuk Res. 2019;78:36-44.
    PubMed     Text format     Abstract available


    February 2019
  64. JARAMILLO AC, Cloos J, Lemos C, Stam RW, et al
    Ex vivo resistance in childhood acute lymphoblastic leukemia: Correlations between BCRP, MRP1, MRP4 and MRP5 ABC transporter expression and intracellular methotrexate polyglutamate accumulation.
    Leuk Res. 2019;79:45-51.
    PubMed     Text format     Abstract available


  65. KING AC, Pappacena JJ, Tallman MS, Park JH, et al
    Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia.
    Leuk Res. 2019;79:27-33.
    PubMed     Text format     Abstract available


  66. SPACEK M, Obrtlikova P, Hrobkova S, Cmunt E, et al
    Prospective observational study in comorbid patients with chronic lymphocytic leukemia receiving first-line bendamustine with rituximab.
    Leuk Res. 2019;79:17-21.
    PubMed     Text format     Abstract available


  67. RADIVOYEVITCH T, Jorgensen TN, Lindner DJ, Maciejewski JP, et al
    Chronic myeloid leukemia: Two mysteries.
    Leuk Res. 2019;79:3-5.
    PubMed     Text format    


  68. DIAB M, Schiffer CA
    The spectrum of musculoskeletal symptoms in patients with chronic myeloid leukemia after stopping tyrosine kinase inhibitors.
    Leuk Res. 2019;79:1-2.
    PubMed     Text format    


  69. DRUSBOSKY LM, Vidva R, Gera S, Lakshminarayana AV, et al
    Predicting response to BET inhibitors using computational modeling: A BEAT AML project study.
    Leuk Res. 2019;77:42-50.
    PubMed     Text format     Abstract available


  70. SAYAR H, Cripe LD, Saliba AN, Abu Zaid M, et al
    Combination of sorafenib, vorinostat and bortezomib for the treatment of poor-risk AML: report of two consecutive clinical trials.
    Leuk Res. 2019;77:30-33.
    PubMed     Text format    


  71. LUO H, Zhang S, Li K, Chen XH, et al
    A novel entity of acute myeloid leukaemia with recurrent RARG-rearrangement resembling acute promyelocytic leukaemia.
    Leuk Res. 2019;77:14-16.
    PubMed     Text format    


    January 2019
  72. BELL JA, Galaznik A, Farrelly E, Blazer M, et al
    A retrospective study evaluating treatment patterns and survival outcomes in elderly patients with acute myeloid leukemia treated in the United States with either 7+3 or a hypomethylating agent.
    Leuk Res. 2019;78:45-51.
    PubMed     Text format     Abstract available


  73. MEDEIROS BC, Othus M, Tallman MS, Sun Z, et al
    The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900).
    Leuk Res. 2019;78:29-33.
    PubMed     Text format     Abstract available


  74. BUDNIK J, Milano MT
    A registry-based analysis of survival outcomes in mast cell leukemia.
    Leuk Res. 2019;78:24-28.
    PubMed     Text format     Abstract available


  75. CIANGOLA G, Gurnari C, Paterno G, Mirabile M, et al
    STAT5b-RARa-positive acute myeloid leukemia: Diagnostic and therapeutic challenges of a rare AML subtype.
    Leuk Res. 2019;78:21-23.
    PubMed     Text format    


  76. LI L, Cui Y, Shen J, Dobson H, et al
    Evidence for activated Lck protein tyrosine kinase as the driver of proliferation in acute myeloid leukemia cell, CTV-1.
    Leuk Res. 2019;78:12-20.
    PubMed     Text format     Abstract available


  77. KUMAR A, Drusbosky LM, Meacham A, Turcotte M, et al
    Computational modeling of early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) to identify personalized therapy using genomics.
    Leuk Res. 2019;78:3-11.
    PubMed     Text format     Abstract available


  78. HENRY D, Brumaire S, Hu X
    Involvement of pRb-E2F pathway in green tea extract-induced growth inhibition of human myeloid leukemia cells.
    Leuk Res. 2019;77:34-41.
    PubMed     Text format     Abstract available


  79. FRIES C, Burack R
    An evolving technology for an evolving disease: A commentary on NGS-based MRD evaluation in B-ALL.
    Leuk Res. 2019;76:105-106.
    PubMed     Text format    


  80. HEIBLIG M, Sujobert P, Hayette S, Balsat M, et al
    Impact of NPM1 mutation subtypes on treatment outcome in AML: The Lyon-University Hospital experience.
    Leuk Res. 2019;76:29-32.
    PubMed     Text format    


  81. MARTINEZ-CUADRON D, Gil C, Serrano J, Rodriguez G, et al
    A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients.
    Leuk Res. 2019;76:1-10.
    PubMed     Text format     Abstract available


    December 2018
  82. KAMATH GR, Tremblay D, Coltoff A, Caro J, et al
    Differences in the clinical and genetic profile of Hispanic and non-Hispanic acute myeloid leukemia patients.
    Leuk Res. 2018;77:1-4.
    PubMed     Text format    


  83. KIM HS, Han E, Jang W, Kim M, et al
    Germline CEBPA mutations in Korean patients with acute myeloid leukemia.
    Leuk Res. 2018 Dec 11. pii: S0145-2126(18)30490.
    PubMed     Text format    


  84. LETENDRE P, Doll D
    Novel therapeutics in the treatment of hairy cell leukemia variant.
    Leuk Res. 2018;75:58-60.
    PubMed     Text format    


    November 2018
  85. DE QUEIROZ MENDONCA C, Freire MV, Viana SS, Silva Tavares MKG, et al
    Ocular manifestations in acute lymphoblastic leukemia: A five-year cohort study of pediatric patients.
    Leuk Res. 2018;76:24-28.
    PubMed     Text format     Abstract available


  86. FILI C, Candoni A, Zannier ME, Olivieri J, et al
    Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience.
    Leuk Res. 2018;76:33-38.
    PubMed     Text format     Abstract available


  87. KANG KH, Kim SH, Choi SY, Yoo HL, et al
    Compound mutations involving T315I and P-loop mutations are the major components of multiple mutations detected in tyrosine kinase inhibitor resistant chronic myeloid leukemia.
    Leuk Res. 2018 Nov 27. pii: S0145-2126(18)30444.
    PubMed     Text format     Abstract available


  88. BROOIMANS RA, van der Velden VHJ, Boeckx N, Slomp J, et al
    Immunophenotypic measurable residual disease (MRD) in acute myeloid leukemia: Is multicentric MRD assessment feasible?
    Leuk Res. 2018;76:39-47.
    PubMed     Text format     Abstract available


  89. NAARMANN-DE VRIES IS, Sackmann Y, Klein F, Ostareck-Lederer A, et al
    Characterization of acute myeloid leukemia with del(9q) - Impact of the genes in the minimally deleted region.
    Leuk Res. 2018;76:15-23.
    PubMed     Text format     Abstract available


  90. DA ROSA FC, Buque Pardinho R, Schultz Moreira ME, de Souza LGT, et al
    In vitro stability of arsenic trioxide-liposome encapsulates for acute promyelocytic leukemia treatment.
    Leuk Res. 2018;76:11-14.
    PubMed     Text format     Abstract available


  91. ITONAGA H, Ota S, Ikeda T, Taji H, et al
    Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: A retrospective nationwide study in Japan.
    Leuk Res. 2018;75:50-57.
    PubMed     Text format     Abstract available


  92. ANDO N, Furuichi Y, Kasai S, Tamai M, et al
    Chemosensitivity is differentially regulated by the SDF-1/CXCR4 and SDF-1/CXCR7 axes in acute lymphoblastic leukemia with MLL gene rearrangements.
    Leuk Res. 2018;75:36-44.
    PubMed     Text format     Abstract available


  93. FRIES C, Burack WR
    A clinical perspective on immunoglobulin heavy chain clonal heterogeneity in B cell acute lymphoblastic leukemia.
    Leuk Res. 2018;75:15-22.
    PubMed     Text format     Abstract available


  94. JAKOVIC L, Bogdanovic A, Djordjevic V, Dencic-Fekete M, et al
    The predictive value of morphological findings in early diagnosis of acute myeloid leukemia with recurrent cytogenetic abnormalities.
    Leuk Res. 2018;75:23-28.
    PubMed     Text format     Abstract available


  95. RAJ RV, Abedin SM, Atallah E
    Incorporating newer agents in the treatment of acute myeloid leukemia.
    Leuk Res. 2018;74:113-120.
    PubMed     Text format     Abstract available


    October 2018
  96. HUAN C, Jin L, Heng W, Na A, et al
    MXD1 regulates the imatinib resistance of chronic myeloid leukemia cells by repressing BCR-ABL1 expression.
    Leuk Res. 2018;75:1-6.
    PubMed     Text format     Abstract available


  97. VACHHANI P, Al Yacoub R, Miller A, Zhang F, et al
    Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experience.
    Leuk Res. 2018;75:29-35.
    PubMed     Text format     Abstract available


  98. THEUNISSEN PMJ, de Bie M, van Zessen D, de Haas V, et al
    Next-generation antigen receptor sequencing of paired diagnosis and relapse samples of B-cell acute lymphoblastic leukemia: Clonal evolution and implications for minimal residual disease target selection.
    Leuk Res. 2018 Oct 22. pii: S0145-2126(18)30443.
    PubMed     Text format     Abstract available


  99. ARABANIAN LS, Johansson P, Staffas A, Nilsson T, et al
    The endothelin receptor type A is a downstream target of Hoxa9 and Meis1 in acute myeloid leukemia.
    Leuk Res. 2018 Oct 13. pii: S0145-2126(18)30430.
    PubMed     Text format     Abstract available


  100. SWEET K, Hazlehurst L, Sahakian E, Powers J, et al
    A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease.
    Leuk Res. 2018;74:89-96.
    PubMed     Text format     Abstract available


  101. BONIFACIO M, Scaffidi L, Binotto G, Miggiano MC, et al
    Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy.
    Leuk Res. 2018;74:75-79.
    PubMed     Text format     Abstract available


  102. MEDEIROS BC
    Chemotherapy based combinations in AML: Time to take a step back?
    Leuk Res. 2018;73:39-40.
    PubMed     Text format    


    September 2018
  103. ESKAZAN AE, Tiribelli M
    Does switching to a second-generation tyrosine kinase inhibitor or increasing imatinib dose have long-term benefits in chronic myeloid leukemia patients with suboptimal responses under upfront standard-dose of imatinib?
    Leuk Res. 2018;74:55-56.
    PubMed     Text format    


  104. CHONG ML, Cheng H, Xu P, You H, et al
    TFG-RARA: A novel fusion gene in acute promyelocytic leukemia that is responsive to all-trans retinoic acid.
    Leuk Res. 2018;74:51-54.
    PubMed     Text format    


  105. JAMY O, Bae S, Costa LJ, Erba HP, et al
    Outcomes of fludarabine, high dose cytarabine and granulocyte-colony stimulating factor (FLAG) as re-induction for residual acute myeloid leukemia on day 14 bone marrow.
    Leuk Res. 2018;74:64-67.
    PubMed     Text format     Abstract available


  106. NAKAMURA Y, Ichikawa M, Oda H, Yamazaki I, et al
    RUNX1-EVI1 induces dysplastic hematopoiesis and acute leukemia of the megakaryocytic lineage in mice.
    Leuk Res. 2018;74:14-20.
    PubMed     Text format     Abstract available


  107. BRASSESCO MS, Pezuk JA, Cortez MA, Bezerra Salomao K, et al
    TLE1 as an indicator of adverse prognosis in pediatric acute lymphoblastic leukemia.
    Leuk Res. 2018;74:42-46.
    PubMed     Text format     Abstract available


  108. PODSHIVALOVA K, Wang EA, Hart T, Salomon DR, et al
    Expression of the miR-150 tumor suppressor is restored by and synergizes with rapamycin in a human leukemia T-cell line.
    Leuk Res. 2018;74:1-9.
    PubMed     Text format     Abstract available


  109. BRUNNER AM, Kim PG, Sadrzadeh H, Drapkin BJ, et al
    Clustered incidence of adult acute promyelocytic leukemia.
    Leuk Res. 2018;74:47-50.
    PubMed     Text format    


  110. TODOERTI K, Calice G, Trino S, Simeon V, et al
    Global methylation patterns in primary plasma cell leukemia.
    Leuk Res. 2018;73:95-102.
    PubMed     Text format     Abstract available


  111. DE CARVALHO DC, Wanderley AV, Dos Santos AMR, Fernandes MR, et al
    Pharmacogenomics and variations in the risk of toxicity during the consolidation/maintenance phases of the treatment of pediatric B-cell leukemia patients from an admixed population in the Brazilian Amazon.
    Leuk Res. 2018;74:10-13.
    PubMed     Text format     Abstract available


  112. BLOCH J, Spertini O, Stucki A, Solly F, et al
    Over 20 years of treatment-free remission after interferon-alpha monotherapy for chronic myeloid leukemia.
    Leuk Res. 2018;73:103-104.
    PubMed     Text format    


  113. TALATI C, Sweet K
    Recently approved therapies in acute myeloid leukemia: A complex treatment landscape.
    Leuk Res. 2018;73:58-66.
    PubMed     Text format     Abstract available


  114. SAVOIE ML, Bence-Bruckler I, Huebsch LB, Lalancette M, et al
    Canadian chronic myeloid leukemia outcomes post-transplant in the tyrosine kinase inhibitor era.
    Leuk Res. 2018;73:67-75.
    PubMed     Text format     Abstract available


  115. WU H, Liu B, Li B, Wang Y, et al
    Granular B-acute lymphoblastic leukemia: Ultrastructural characterization of cytoplasmic granules.
    Leuk Res. 2018;73:105-107.
    PubMed     Text format    


  116. SOMMER S, Cruijsen M, Claus R, Bertz H, et al
    Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation.
    Leuk Res. 2018;72:20-26.
    PubMed     Text format     Abstract available


    August 2018
  117. FERREYRO BL, Munshi L, Detsky ME, Minden MD, et al
    Acute promyelocytic leukemia in the intensive care unit: A retrospective analysis.
    Leuk Res. 2018;73:41-43.
    PubMed     Text format    


  118. HUDSON CA, Burack WR, Bennett JM
    Emerging utility of flow cytometry in the diagnosis of chronic myelomonocytic leukemia.
    Leuk Res. 2018;73:12-15.
    PubMed     Text format     Abstract available


  119. LI D, Lin TL, Lipe B, Hopkins RA, et al
    A novel extracellular matrix-based leukemia model supports leukemia cells with stem cell-like characteristics.
    Leuk Res. 2018;72:105-112.
    PubMed     Text format     Abstract available


  120. CHEN X, Wang F, Zhang Y, Wang M, et al
    Retrospective analysis of 36 fusion genes in 2479 Chinese patients of de novo acute lymphoblastic leukemia.
    Leuk Res. 2018;72:99-104.
    PubMed     Text format     Abstract available


  121. DHANGAR S, C SK, S C, Vundinti BR, et al
    Imatinib resistance due to a novel and rare class of mutation at position S348 (1043nt C-->A) of Bcr/Abl gene in a chronic myeloid leukemia patient.
    Leuk Res. 2018;72:96-98.
    PubMed     Text format    


  122. ZEIDNER JF, Foster MC, Blackford AL, Litzow MR, et al
    Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML).
    Leuk Res. 2018;72:92-95.
    PubMed     Text format    


  123. MANUKYAN G, Turcsanyi P, Mikulkova Z, Gabcova G, et al
    Dynamic changes in HLA-DR expression during short-term and long-term ibrutinib treatment in patients with chronic lymphocytic leukemia.
    Leuk Res. 2018;72:113-119.
    PubMed     Text format     Abstract available


  124. LEI H, Yang L, Zhou L, Tong Y, et al
    Targeting acute myeloid leukemia CD34(+) stem/progenitor cells with small molecule inhibitor MK-8776.
    Leuk Res. 2018;72:71-73.
    PubMed     Text format    


  125. NAIR RR, Piktel D, Geldenhuys WJ, Gibson LF, et al
    Combination of cabazitaxel and plicamycin induces cell death in drug resistant B-cell acute lymphoblastic leukemia.
    Leuk Res. 2018;72:59-66.
    PubMed     Text format     Abstract available


    July 2018
  126. FERRARO F, Gao F, Stockerl-Goldstein K, Westervelt P, et al
    Secondary acute lymphoblastic leukemia, a retrospective analysis from Washington University and meta-analysis of published data.
    Leuk Res. 2018;72:86-91.
    PubMed     Text format     Abstract available


  127. DARVISHI M, Mashati P, Khosravi A
    The clinical significance of CDX2 in leukemia: A new perspective for leukemia research.
    Leuk Res. 2018;72:45-51.
    PubMed     Text format     Abstract available


  128. WANG YZ, Hao L, Chang Y, Jiang Q, et al
    A seven-color panel including CD34 and TdT could be applied in >97% patients with T cell lymphoblastic leukemia for minimal residual disease detection independent of the initial phenotype.
    Leuk Res. 2018;72:12-19.
    PubMed     Text format     Abstract available


  129. ROUSSELOT P, Renard P, de Buyer A, Finet A, et al
    Nivolumab to control molecular response in chronic myeloid leukemia.
    Leuk Res. 2018;72:5-6.
    PubMed     Text format    


  130. HEIBLIG M, Elhamri M, Thomas X, Plesa A, et al
    A phase 1 study of chemosensitization with plerixafor plus G-CSF in adults with relapsed acute myeloid leukemia.
    Leuk Res. 2018;72:7-11.
    PubMed     Text format    


  131. RADIVOYEVITCH T, Dean RM, Shaw BE, Brazauskas R, et al
    Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma.
    Leuk Res. 2018 Jul 19. pii: S0145-2126(18)30160.
    PubMed     Text format     Abstract available


  132. GU Y, Han Q, McGrath M, Song C, et al
    Clinical significance of novel SH2B3 mutations in adult Chinese acute lymphoblastic leukemia patients.
    Leuk Res. 2018;72:67-70.
    PubMed     Text format    


  133. MARZ M, Meyer S, Erb U, Georgikou C, et al
    Pediatric acute lymphoblastic leukemia-Conquering the CNS across the choroid plexus.
    Leuk Res. 2018;71:47-54.
    PubMed     Text format     Abstract available


  134. ARCHIBALD WJ, Meacham PJ, Williams AM, Baran AM, et al
    Management of melanoma in patients with chronic lymphocytic leukemia.
    Leuk Res. 2018;71:43-46.
    PubMed     Text format     Abstract available


    June 2018
  135. WARRICK K, Althouse SK, Rahrig A, Rupenthal J, et al
    Factors associated with a prolonged hospital stay during induction chemotherapy in newly diagnosed high risk pediatric acute lymphoblastic leukemia.
    Leuk Res. 2018;71:36-42.
    PubMed     Text format     Abstract available


  136. BELL JA, Galaznik A, Farrelly E, Blazer M, et al
    Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States.
    Leuk Res. 2018;71:27-33.
    PubMed     Text format     Abstract available


  137. ROSSI JG, Rubio P, Alonso CN, Bernasconi AR, et al
    Cytoplasmic CD3 expression in infant acute megakaryoblastic leukemia: A new ambiguous lineage subtype?
    Leuk Res. 2018;71:6-12.
    PubMed     Text format     Abstract available


  138. PAN T, Qi J, You T, Yang L, et al
    Addition of histone deacetylase inhibitors does not improve prognosis in patients with myelodysplastic syndrome and acute myeloid leukemia compared with hypomethylating agents alone: A systematic review and meta-analysis of seven prospective cohort st
    Leuk Res. 2018;71:13-24.
    PubMed     Text format     Abstract available


  139. GAVILLET M, Spertini O, Blum S
    Pseudo Chediak-Higashi anomaly in blasts from acute lymphoblastic leukemia.
    Leuk Res. 2018;70:87-90.
    PubMed     Text format    


  140. DAS S, Dielschneider R, Chanas-LaRue A, Johnston JB, et al
    Antimalarial drugs trigger lysosome-mediated cell death in chronic lymphocytic leukemia (CLL) cells.
    Leuk Res. 2018;70:79-86.
    PubMed     Text format     Abstract available


  141. BRYANT AL, Drier SW, Lee S, Bennett AV, et al
    A systematic review of patient reported outcomes in phase II or III clinical trials of myelodysplastic syndromes and acute myeloid leukemia.
    Leuk Res. 2018;70:106-116.
    PubMed     Text format     Abstract available


  142. LEE SE, Choi SY, Kim SH, Jootar S, et al
    Comparative analyses of nilotinib versus high-dose imatinib versus sustained standard-dose imatinib in patients with chronic phase chronic myeloid leukemia following suboptimal molecular response to first-line imatinib.
    Leuk Res. 2018;70:100-105.
    PubMed     Text format     Abstract available


  143. LIU C, Wei H, Yao X, Liu B, et al
    Retraction notice to "Arsenic Trioxide Inhibits Proliferation and Induced apoptosis of Leukemia Stem Cells with Drug Resistance " [LR 69 (2018) 66-71].
    Leuk Res. 2018;69:103.
    PubMed     Text format    


  144. VULAJ V, Perissinotti AJ, Uebel JR, Nachar VR, et al
    The FOSSIL Study: FLAG or standard 7+3 induction therapy in secondary acute myeloid leukemia.
    Leuk Res. 2018;70:91-96.
    PubMed     Text format     Abstract available


  145. WANG ES, O'Dwyer K
    High dose daunorubicin: New standard of care for FLT3 ITD mutant AML.
    Leuk Res. 2018;69:87-88.
    PubMed     Text format    


  146. CHEN Z, Kapus A, Khatri I, Kos O, et al
    Cell membrane-bound CD200 signals both via an extracellular domain and following nuclear translocation of a cytoplasmic fragment.
    Leuk Res. 2018;69:72-80.
    PubMed     Text format     Abstract available


    May 2018
  147. WANG W, Routbort MJ, Loghavi S, Tang Z, et al
    Characterization of chronic myelomonocytic leukemia with TP53 mutations.
    Leuk Res. 2018;70:97-99.
    PubMed     Text format    


  148. XICOY B, Triguero A, Such E, Garcia O, et al
    The division of chronic myelomonocytic leukemia (CMML)-1 into CMML-0 and CMML-1 according to 2016 World Health Organization (WHO) classification has no impact in outcome in a large series of patients from the Spanish group of MDS.
    Leuk Res. 2018;70:34-36.
    PubMed     Text format    


  149. MADAROVA M, Mucha R, Hresko S, Makarova Z, et al
    Identification of new phosphorylation sites of CD23 in B-cells of patients with chronic lymphocytic leukemia.
    Leuk Res. 2018;70:25-33.
    PubMed     Text format     Abstract available


  150. SMITH MR, Weiss RF
    Optimal use of novel agents in chronic lymphocytic leukemia.
    Leuk Res. 2018;70:37-40.
    PubMed     Text format     Abstract available


  151. HUANG J, Wang Z, Huang L, Zheng M, et al
    Corrigendum to 'CD41 immune staining of micromegakaryocytes improves the diagnosis of myelodysplastic syndrome and differentiation from pancytopenia' [leukemia research. 2018; 66: 15-19].
    Leuk Res. 2018;68:120.
    PubMed     Text format    


  152. SHOKRI G, Doudi S, Fathi-Roudsari M, Kouhkan F, et al
    Targeting histone demethylases KDM5A and KDM5B in AML cancer cells: A comparative view.
    Leuk Res. 2018;68:105-111.
    PubMed     Text format     Abstract available


  153. ZHU F, Khatri I, Spaner D, Gorczynski RM, et al
    An autologous tumor vaccine for CLL.
    Leuk Res. 2018;68:40-47.
    PubMed     Text format     Abstract available


  154. KAVANAGH S, Heath E, Hurren R, Gronda M, et al
    AML refractory to primary induction with Ida-FLAG has a poor clinical outcome.
    Leuk Res. 2018;68:22-28.
    PubMed     Text format     Abstract available


  155. LIU J, Lu W, Liu S, Wang Y, et al
    ZFP36L2, a novel AML1 target gene, induces AML cells apoptosis and inhibits cell proliferation.
    Leuk Res. 2018;68:15-21.
    PubMed     Text format     Abstract available


  156. IRIYAMA N, Takahashi H, Miura K, Uchino Y, et al
    Enhanced perforin expression associated with dasatinib therapy in natural killer cells.
    Leuk Res. 2018;68:1-8.
    PubMed     Text format     Abstract available


    April 2018
  157. PAPAGEORGIOU SG, Kontos CK, Tsiakanikas P, Stavroulaki G, et al
    Elevated miR-20b-5p expression in peripheral blood mononuclear cells: A novel, independent molecular biomarker of favorable prognosis in chronic lymphocytic leukemia.
    Leuk Res. 2018;70:1-7.
    PubMed     Text format     Abstract available


  158. TAN Y, Liu Z, Wang W, Zhu G, et al
    Monitoring of clonal evolution of double C-KIT exon 17 mutations by Droplet Digital PCR in patients with core-binding factor acute myeloid leukemia.
    Leuk Res. 2018;69:89-93.
    PubMed     Text format     Abstract available


  159. ZHANG M, Yin J, He Q, Zhang F, et al
    Chinese and Europeans with acute myeloid leukemia have discordant mutation topographies.
    Leuk Res. 2018;70:8-12.
    PubMed     Text format     Abstract available


  160. DELORD M, Foulon S, Cayuela JM, Rousselot P, et al
    The rising prevalence of chronic myeloid leukemia in France.
    Leuk Res. 2018;69:94-99.
    PubMed     Text format     Abstract available


  161. TANG L, Wang N, Xing C, Zhuang Q, et al
    Effect of absolute monocyte count post-transplant on the outcome of patients with acute myeloid leukemia undergoing myeloablative allogeneic hematopoietic stem cell transplant with busulfan and cyclophosphamide conditioning.
    Leuk Res. 2018;69:60-65.
    PubMed     Text format     Abstract available


  162. GROHMANN T, Penke M, Petzold-Quinque S, Schuster S, et al
    Inhibition of NAMPT sensitizes MOLT4 leukemia cells for etoposide treatment through the SIRT2-p53 pathway.
    Leuk Res. 2018;69:39-46.
    PubMed     Text format     Abstract available


  163. GHAVAMZADEH A, Jalili M, Rostami S, Yaghmaie M, et al
    Corrigendum to: Comparison of Induction Therapy in Non-high Risk Acute Promyelocytic Leukemia with Arsenic Trioxide or in Combination with ATRA Leukemia Research 66 (2018) 85-88.
    Leuk Res. 2018;67:116.
    PubMed     Text format    


  164. WANG YH, Imai Y, Shiseki M, Tanaka J, et al
    Knockdown of the Wnt receptor Frizzled-1 (FZD1) reduces MDR1/P-glycoprotein expression in multidrug resistant leukemic cells and inhibits leukemic cell proliferation.
    Leuk Res. 2018;67:99-108.
    PubMed     Text format     Abstract available


  165. ANNIBALI O, Crescenzi A, Tomarchio V, Pagano A, et al
    PD-1 /PD-L1 checkpoint in hematological malignancies.
    Leuk Res. 2018;67:45-55.
    PubMed     Text format     Abstract available


    March 2018
  166. PEHLIVAN M, Caliskan C, Yuce Z, Sercan HO, et al
    Secreted Wnt antagonists in leukemia: A road yet to be paved.
    Leuk Res. 2018;69:24-30.
    PubMed     Text format     Abstract available


  167. LAM CF, Yeung HT, Lam YM, Ng RK, et al
    Reactive oxygen species activate differentiation gene transcription of acute myeloid leukemia cells via the JNK/c-JUN signaling pathway.
    Leuk Res. 2018;68:112-119.
    PubMed     Text format     Abstract available


  168. SAROVA I, Brezinova J, Zemanova Z, Ransdorfova S, et al
    High frequency of dicentric chromosomes detected by multi-centromeric FISH in patients with acute myeloid leukemia and complex karyotype.
    Leuk Res. 2018;68:85-89.
    PubMed     Text format     Abstract available


  169. RIBERA JM, Garcia O, Gil C, Mercadal S, et al
    Comparison of intensive, pediatric-inspired therapy with non-intensive therapy in older adults aged 55-65 years with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Leuk Res. 2018;68:79-84.
    PubMed     Text format     Abstract available


  170. CHOI EJ, Lee JH, Lee JH, Park HS, et al
    Comparison of anthracyclines used for induction chemotherapy in patients with FLT3-ITD-mutated acute myeloid leukemia.
    Leuk Res. 2018;68:51-56.
    PubMed     Text format     Abstract available


  171. SEDDON AN, Chaim J, Akin O, Drill E, et al
    Similar incidence of typhlitis in patients receiving various doses of daunorubicin or idarubicin as induction for acute myeloid leukemia.
    Leuk Res. 2018;68:48-50.
    PubMed     Text format     Abstract available


  172. SCHOEN MW, Woelich SK, Braun JT, Reddy DV, et al
    Acute myeloid leukemia induction with cladribine: Outcomes by age and leukemia risk.
    Leuk Res. 2018;68:72-78.
    PubMed     Text format     Abstract available


  173. DAI Q, Liu X, Yang H, Guo S, et al
    No prognostic significance of immunophenotypic changes at the end of remission induction therapy in children with B-lineage acute lymphoblastic leukemia.
    Leuk Res. 2018;68:57-61.
    PubMed     Text format     Abstract available


  174. LIU C, Wei H, Yao X, Liu B, et al
    Arsenic trioxide inhibits proliferation and induced apoptosis of leukemia stem cells with drug resistance.
    Leuk Res. 2018;69:66-71.
    PubMed     Text format     Abstract available


  175. GANZEL C, Rouvio O, Avivi I, Magen H, et al
    Primary plasma cell leukemia in the era of novel agents for myeloma - a multicenter retrospective analysis of outcome.
    Leuk Res. 2018;68:9-14.
    PubMed     Text format     Abstract available


  176. SINGH M, Bhatia P, Trehan A, Varma N, et al
    High frequency of intermediate and poor risk copy number abnormalities in pediatric cohort of B-ALL correlate with high MRD post induction.
    Leuk Res. 2018;66:79-84.
    PubMed     Text format     Abstract available


  177. NAJIMA Y, Yoshida C, Iriyama N, Fujisawa S, et al
    Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response-The final results of the D-first study.
    Leuk Res. 2018;66:66-72.
    PubMed     Text format     Abstract available


    February 2018
  178. SAILLARD C, Elkaim E, Rey J, d'Incan E, et al
    Early preemptive ICU admission for newly diagnosed high-risk acute myeloid leukemia patients.
    Leuk Res. 2018;68:29-31.
    PubMed     Text format    


  179. HIWASE D, Tan P, D'Rozario J, Taper J, et al
    Efficacy and safety of nilotinib 300mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.
    Leuk Res. 2018;67:109-115.
    PubMed     Text format     Abstract available


  180. DECKERT AL, Gheihman G, Nissim R, Chung C, et al
    The importance of meaningful activity in people living with acute myeloid leukemia.
    Leuk Res. 2018;67:86-91.
    PubMed     Text format     Abstract available


  181. LI X, Li D, Huang X, Zhou P, et al
    Helios expression in regulatory T cells promotes immunosuppression, angiogenesis and the growth of leukemia cells in pediatric acute lymphoblastic leukemia.
    Leuk Res. 2018;67:60-66.
    PubMed     Text format     Abstract available


  182. EPSTEIN-PETERSON ZD, Devlin SM, Stein EM, Estey E, et al
    Widespread use of measurable residual disease in acute myeloid leukemia practice.
    Leuk Res. 2018;67:92-98.
    PubMed     Text format     Abstract available


  183. MEDEIROS BC
    Interpretation of clinical endpoints in trials of acute myeloid leukemia.
    Leuk Res. 2018;68:32-39.
    PubMed     Text format     Abstract available


  184. TOSIC N, Petrovic I, Grujicic NK, Davidovic S, et al
    Prognostic significance of SOX2, SOX3, SOX11, SOX14 and SOX18 gene expression in adult de novo acute myeloid leukemia.
    Leuk Res. 2018;67:32-38.
    PubMed     Text format     Abstract available


  185. BLAKLEY MP, Dutcher JP, Wiernik PH
    Pulmonary Langerhans cell histiocytosis, acute myeloid leukemia, and myelofibrosis in a large family and review of the literature.
    Leuk Res. 2018;67:39-44.
    PubMed     Text format     Abstract available


  186. HEINRICHS A, Dessars B, El Housni H, Pluymers W, et al
    Identification of chronic myeloid leukemia patients treated with imatinib who are potentially eligible for treatment discontinuation by assessing real-life molecular responses on the international scale in a EUTOS-certified lab.
    Leuk Res. 2018;67:27-31.
    PubMed     Text format     Abstract available


  187. HU Z, Hu S, Ji C, Tang Z, et al
    3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis.
    Leuk Res. 2018;65:25-28.
    PubMed     Text format     Abstract available


  188. SCHULER E, Frank F, Hildebrandt B, Betz B, et al
    Myelodysplastic syndromes without peripheral monocytosis but with evidence of marrow monocytosis share clinical and molecular characteristics with CMML.
    Leuk Res. 2018;65:1-4.
    PubMed     Text format     Abstract available


    January 2018
  189. ADVANI AS, Li H, Michaelis LC, Medeiros BC, et al
    Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML).
    Leuk Res. 2018;67:17-20.
    PubMed     Text format     Abstract available


  190. GHAVAMZADEH A, Jalili M, Rostami S, Yaghmaie M, et al
    Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA.
    Leuk Res. 2018;66:85-88.
    PubMed     Text format     Abstract available


  191. PETITI J, Rosso V, Lo Iacono M, Calabrese C, et al
    Prognostic significance of The Wilms' Tumor-1 (WT1) rs16754 polymorphism in acute myeloid leukemia.
    Leuk Res. 2018;67:6-11.
    PubMed     Text format     Abstract available


  192. DHOLARIA BR, Ayala E, Sokol L, Nishihori T, et al
    Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: A single-center experience.
    Leuk Res. 2018;67:1-5.
    PubMed     Text format     Abstract available


  193. HARADA Y, Nagata Y, Kihara R, Ishikawa Y, et al
    Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study.
    Leuk Res. 2018;66:20-27.
    PubMed     Text format     Abstract available


  194. ZHU F, McCaw L, Spaner DE, Gorczynski RM, et al
    Targeting the IL-17/IL-6 axis can alter growth of Chronic Lymphocytic Leukemia in vivo/in vitro.
    Leuk Res. 2018;66:28-38.
    PubMed     Text format     Abstract available


  195. AMANZADEH A, Molla-Kazemiha V, Samani S, Habibi-Anbouhi M, et al
    New synergistic combinations of differentiation-inducing agents in the treatment of acute promyelocytic leukemia cells.
    Leuk Res. 2018;68:98-104.
    PubMed     Text format     Abstract available


  196. GETTA BM, Devlin S, Park JH, Tallman MS, et al
    Disease characteristics and clinical outcomes in patients aged less than 40 with chronic lymphocytic leukemia.
    Leuk Res. 2018;65:80-85.
    PubMed     Text format     Abstract available


  197. INOKUCHI K, Nakayama K, Tauchi T, Takaku T, et al
    Therapeutic effects of tyrosine kinase inhibitors and subtypes of BCR-ABL1 transcripts in Japanese chronic myeloid leukemia patients with three-way chromosomal translocations.
    Leuk Res. 2018;65:74-79.
    PubMed     Text format     Abstract available


  198. KONG YL, Huang Y, Wu JZ, Cao X, et al
    Expression of autophagy related genes in chronic lymphocytic leukemia is associated with disease course.
    Leuk Res. 2018;66:8-14.
    PubMed     Text format     Abstract available


  199. BURKE PW, Aldoss I, Lunning MA, Devlin SM, et al
    Pegaspargase-related high-grade hepatotoxicity in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not predict recurrent hepatotoxicity with subsequent doses.
    Leuk Res. 2018;66:49-56.
    PubMed     Text format     Abstract available


  200. OKABE-KADO J, Hagiwara-Watanabe Y, Niitsu N, Kasukabe T, et al
    NM23 downregulation and lysophosphatidic acid receptor EDG2/lpa1 upregulation during myeloid differentiation of human leukemia cells.
    Leuk Res. 2018;66:39-48.
    PubMed     Text format     Abstract available


  201. CUI P, Zhang Y, Cui M, Li Z, et al
    Leukemia cells impair normal hematopoiesis and induce functionally loss of hematopoietic stem cells through immune cells and inflammation.
    Leuk Res. 2018;65:49-54.
    PubMed     Text format     Abstract available


  202. KAMIJO R, Itonaga H, Kihara R, Nagata Y, et al
    Distinct gene alterations with a high percentage of myeloperoxidase-positive leukemic blasts in de novo acute myeloid leukemia.
    Leuk Res. 2018;65:34-41.
    PubMed     Text format     Abstract available


  203. JAWOROWSKA A, Pastorczak A, Trelinska J, Wypyszczak K, et al
    Perforin gene variation influences survival in childhood acute lymphoblastic leukemia.
    Leuk Res. 2018;65:29-33.
    PubMed     Text format     Abstract available


  204. STRICKLAND SA, Shaver AC, Byrne M, Daber RD, et al
    Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia.
    Leuk Res. 2018;65:67-73.
    PubMed     Text format     Abstract available


  205. WANG SM, Zeng WX, Wu WS, Sun LL, et al
    Association between a microRNA binding site polymorphism in SLCO1A2 and the risk of delayed methotrexate elimination in Chinese children with acute lymphoblastic leukemia.
    Leuk Res. 2018;65:61-66.
    PubMed     Text format     Abstract available


  206. ZHAO H, Zhu H, Huang J, Zhu Y, et al
    The synergy of Vitamin C with decitabine activates TET2 in leukemic cells and significantly improves overall survival in elderly patients with acute myeloid leukemia.
    Leuk Res. 2018;66:1-7.
    PubMed     Text format     Abstract available


  207. MILLAN NC, Pastrana A, Guitter MR, Zubizarreta PA, et al
    Acute and sub-acute neurological toxicity in children treated for acute lymphoblastic leukemia.
    Leuk Res. 2018;65:86-93.
    PubMed     Text format     Abstract available


  208. MIYATA S, Wang LY, Kitanaka S
    3EZ, 20Ac-ingenol induces cell-specific apoptosis in cyclin D1 over-expression through the activation of ATR and downregulation of p-Akt.
    Leuk Res. 2018;64:46-51.
    PubMed     Text format     Abstract available


  209. GARCIA TB, Fosmire SP, Porter CC
    Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabine.
    Leuk Res. 2018;64:30-33.
    PubMed     Text format     Abstract available


    December 2017
  210. ZHAN D, Zhang Y, Xiao P, Zheng X, et al
    Whole exome sequencing identifies novel mutations of epigenetic regulators in chemorefractory pediatric acute myeloid leukemia.
    Leuk Res. 2017;65:20-24.
    PubMed     Text format     Abstract available


  211. CULL AH, Mahendru D, Snetsinger B, Good D, et al
    Overexpression of Arginase 1 is linked to DNMT3A and TET2 mutations in lower-grade myelodysplastic syndromes and chronic myelomonocytic leukemia.
    Leuk Res. 2017;65:5-13.
    PubMed     Text format     Abstract available


  212. SEBERT M, Komrokji RS, Sekeres MA, Prebet T, et al
    Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine.
    Leuk Res. 2017;63:72-77.
    PubMed     Text format     Abstract available


  213. KOJIMA S, Nishioka C, Chi S, Yokoyama A, et al
    In vitro studies on the role of recombinant human soluble thrombomodulin in the context of retinoic acid mediated APL differentiation syndrome.
    Leuk Res. 2017;63:1-9.
    PubMed     Text format     Abstract available


    November 2017
  214. PANDO A, Reagan JL, Quesenberry P, Fast LD, et al
    Extracellular vesicles in leukemia.
    Leuk Res. 2017;64:52-60.
    PubMed     Text format     Abstract available


  215. ZHU HH, Guo ZP, Jia JS, Jiang Q, et al
    The impact of oral arsenic and all-trans-retinoic acid on coagulopathy in acute promyelocytic leukemia.
    Leuk Res. 2017;65:14-19.
    PubMed     Text format     Abstract available


  216. LEI H, Jin J, Liu M, Li X, et al
    Chk1 inhibitors overcome imatinib resistance in chronic myeloid leukemia cells.
    Leuk Res. 2017;64:17-23.
    PubMed     Text format     Abstract available


  217. NAVADA SC, Fruchtman SM, Odchimar-Reissig R, Demakos EP, et al
    A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia.
    Leuk Res. 2017;64:10-16.
    PubMed     Text format     Abstract available


  218. SWORDS RT, Azzam D, Al-Ali H, Lohse I, et al
    Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study.
    Leuk Res. 2017;64:34-41.
    PubMed     Text format     Abstract available


  219. SAJWANI FH, Collin P, Adrian TE
    Frondoside A potentiates the effects of conventional therapeutic agents in acute leukemia.
    Leuk Res. 2017;63:98-108.
    PubMed     Text format     Abstract available


  220. NACHAR VR, Perissinotti AJ, Scappaticci GB, Bixby DL, et al
    Predictors for requiring re-induction chemotherapy in acute myeloid leukemia patients with residual disease on day 14 bone marrow assessment.
    Leuk Res. 2017;63:56-61.
    PubMed     Text format     Abstract available


  221. TAN M, Rong Y, Su Q, Chen Y, et al
    Artesunate induces apoptosis via inhibition of STAT3 in THP-1 cells.
    Leuk Res. 2017;62:98-103.
    PubMed     Text format     Abstract available


  222. SINGH M, Bhatia P, Khera S, Trehan A, et al
    Emerging role of NUDT15 polymorphisms in 6-mercaptopurine metabolism and dose related toxicity in acute lymphoblastic leukaemia.
    Leuk Res. 2017;62:17-22.
    PubMed     Text format     Abstract available


    October 2017
  223. OZDOGAN H, Gur Dedeoglu B, Oztemur Islakoglu Y, Aydos A, et al
    DICER1 gene and miRNA dysregulation in mesenchymal stem cells of patients with myelodysplastic syndrome and acute myeloblastic leukemia.
    Leuk Res. 2017;63:62-71.
    PubMed     Text format     Abstract available


  224. ERIKSSON A, Chantzi E, Fryknas M, Gullbo J, et al
    Towards repositioning of quinacrine for treatment of acute myeloid leukemia - Promising synergies and in vivo effects.
    Leuk Res. 2017;63:41-46.
    PubMed     Text format     Abstract available


  225. NOMDEDEU M, Pereira A, Calvo X, Colomer J, et al
    Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group.
    Leuk Res. 2017;63:85-89.
    PubMed     Text format     Abstract available


  226. ZHAO WH, Huang BT, Zhang JY, Zeng QC, et al
    Distinct EphB4-mediated mechanisms of apoptotic and resistance to dasatinib in human chronic myeloid leukemia and K562 cell lines.
    Leuk Res. 2017;63:28-33.
    PubMed     Text format     Abstract available


  227. CANDONI A, De Marchi F, Zannier ME, Lazzarotto D, et al
    High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
    Leuk Res. 2017;63:22-27.
    PubMed     Text format     Abstract available


  228. FAKHIMAHMADI A, Nazmi F, Rahmati M, Bonab NM, et al
    Nucleostemin silencing induces differentiation and potentiates all-trans-retinoic acid effects in human acute promyelocytic leukemia NB4 cells via autophagy.
    Leuk Res. 2017;63:15-21.
    PubMed     Text format     Abstract available


  229. MOHAMMADI SM, Mohammadnejad D, Hosseinpour Feizi AA, Movassaghpour AA, et al
    Inhibition of c-REL using siRNA increased apoptosis and decreased proliferation in pre-B ALL blasts: Therapeutic implications.
    Leuk Res. 2017;61:53-61.
    PubMed     Text format     Abstract available


  230. AIRIAU K, Turcq B, Mahon FX, Belloc F, et al
    A new mechanism of resistance to ABL1 tyrosine kinase inhibitors in a BCR-ABL1-positive cell line.
    Leuk Res. 2017;61:44-52.
    PubMed     Text format     Abstract available


    September 2017
  231. HENKENIUS K, Greene BH, Barckhausen C, Hartmann R, et al
    Maintenance of cellular respiration indicates drug resistance in acute myeloid leukemia.
    Leuk Res. 2017;62:56-63.
    PubMed     Text format     Abstract available


  232. AHMED T, Koch AL, Isom S, Klepin HD, et al
    Outcomes and changes in code status of patients with acute myeloid leukemia undergoing induction chemotherapy who were transferred to the intensive care unit.
    Leuk Res. 2017;62:51-55.
    PubMed     Text format     Abstract available


  233. HUANG Y, Zou Y, Lin L, Ma X, et al
    Effect of BIX-01294 on proliferation, apoptosis and histone methylation of acute T lymphoblastic leukemia cells.
    Leuk Res. 2017;62:34-39.
    PubMed     Text format     Abstract available


  234. ZHOU K, Song Y, Zhang Y, Wei X, et al
    Efficacy and safety of G-CSF, low-dose cytarabine and aclarubicin in combination with l-asparaginase, prednisone in the treatment of refractory or relapsed acute lymphoblastic leukemia.
    Leuk Res. 2017;62:29-33.
    PubMed     Text format     Abstract available


  235. VISANI G, Ferrara F, Di Raimondo F, Loscocco F, et al
    Low-dose lenalidomide plus cytarabine in very elderly, unfit acute myeloid leukemia patients: Final result of a phase II study.
    Leuk Res. 2017;62:77-83.
    PubMed     Text format     Abstract available


  236. BOUVY C, Wannez A, Laloy J, Chatelain C, et al
    Transfer of multidrug resistance among acute myeloid leukemia cells via extracellular vesicles and their microRNA cargo.
    Leuk Res. 2017;62:70-76.
    PubMed     Text format     Abstract available


  237. SAHAI T, Henrichs K, Refaai M, Heal JM, et al
    ABO identical and washed blood transfusions as candidate strategies to reduce early mortality in acute promyelocytic leukemia.
    Leuk Res. 2017;62:1-3.
    PubMed     Text format     Abstract available


  238. AZUMA K, Umezu T, Imanishi S, Asano M, et al
    Genetic variations of bone marrow mesenchymal stromal cells derived from acute leukemia and myelodysplastic syndrome by targeted deep sequencing.
    Leuk Res. 2017;62:23-28.
    PubMed     Text format     Abstract available


  239. WEBSTER JA, Tibes R, Morris L, Blackford AL, et al
    Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia.
    Leuk Res. 2017;61:108-116.
    PubMed     Text format     Abstract available


  240. HORSTER L, Schlenk RF, Stadler M, Gabriel M, et al
    Cost-effectiveness of methods in personalized medicine. Results of a decision-analytic model in patients with acute myeloid leukemia with normal karyotype.
    Leuk Res. 2017;62:84-90.
    PubMed     Text format     Abstract available


  241. WANG F, Jia JS, Wang J, Zhao T, et al
    The kinetics of white blood cell and the predictive factors of leukocytosis under oral or intravenous arsenic as the first-line treatment for acute promyelocytic leukemia.
    Leuk Res. 2017;61:84-88.
    PubMed     Text format     Abstract available


  242. DARJI A, Desai N, Modi R, Khamar B, et al
    Establishment of cell line with NK/NKT phenotype from myeloid NK cell acute leukemia.
    Leuk Res. 2017;61:77-83.
    PubMed     Text format     Abstract available


  243. TAMAI M, Furuichi Y, Kasai S, Ando N, et al
    TGFbeta1 synergizes with FLT3 ligand to induce chemoresistant quiescence in acute lymphoblastic leukemia with MLL gene rearrangements.
    Leuk Res. 2017;61:68-76.
    PubMed     Text format     Abstract available


  244. CHEN CY, Chang PC, Wang TH, Wang TV, et al
    The in vivo anti-leukemia activity of N-(1-Pyrenlyl) maleimide in a bioluminescent mouse model.
    Leuk Res. 2017;62:64-69.
    PubMed     Text format     Abstract available


  245. KRUG U, Gale RP, Berdel WE, Muller-Tidow C, et al
    Therapy of older persons with acute myeloid leukaemia.
    Leuk Res. 2017;60:1-10.
    PubMed     Text format     Abstract available


    August 2017
  246. YOUNESIAN S, Shahkarami S, Ghaffari P, Alizadeh S, et al
    DNA hypermethylation of tumor suppressor genes RASSF6 and RASSF10 as independent prognostic factors in adult acute lymphoblastic leukemia.
    Leuk Res. 2017;61:33-38.
    PubMed     Text format     Abstract available


  247. NORSWORTHY KJ, DeZern AE, Tsai HL, Hand WA, et al
    Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature.
    Leuk Res. 2017;61:25-32.
    PubMed     Text format     Abstract available


  248. COMONT T, Tavitian S, Bardiaux L, Fort M, et al
    Platelet transfusion refractoriness in patients with acute myeloid leukemia treated by intensive chemotherapy.
    Leuk Res. 2017;61:62-67.
    PubMed     Text format     Abstract available


  249. FRAIRIA C, Aydin S, Audisio E, Riera L, et al
    Post-remissional and pre-transplant role of minimal residual disease detected by WT1 in acute myeloid leukemia: A retrospective cohort study.
    Leuk Res. 2017;61:10-17.
    PubMed     Text format     Abstract available


  250. CHEN Y, Pourabdollah M, Atenafu EG, Tierens A, et al
    Re-evaluation of acute erythroid leukemia according to the 2016 WHO classification.
    Leuk Res. 2017;61:39-43.
    PubMed     Text format     Abstract available


  251. CAOCCI G, Greco M, Arras M, Cusano R, et al
    HLA-G molecules and clinical outcome in Chronic Myeloid Leukemia.
    Leuk Res. 2017;61:1-5.
    PubMed     Text format     Abstract available


  252. SAKIHAMA S, Saito M, Kuba-Miyara M, Tomoyose T, et al
    Human T-cell leukemia virus type I Tax genotype analysis in Okinawa, the southernmost and remotest islands of Japan: Different distributions compared with mainland Japan and the potential value for the prognosis of aggressive adult T-cell leukemia/lym
    Leuk Res. 2017;61:18-24.
    PubMed     Text format     Abstract available


  253. YAO C, Zhang G, Walker A, Zhao KY, et al
    Potent induction of apoptosis by givinostat in BCR-ABL1-positive and BCR-ABL1-negative precursor B-cell acute lymphoblastic leukemia cell lines.
    Leuk Res. 2017;60:129-134.
    PubMed     Text format     Abstract available


  254. VAVROVA E, Kantorova B, Vonkova B, Kabathova J, et al
    Fragment analysis represents a suitable approach for the detection of hotspot c.7541_7542delCT NOTCH1 mutation in chronic lymphocytic leukemia.
    Leuk Res. 2017;60:145-150.
    PubMed     Text format     Abstract available


  255. MASAROVA L, Bose P, Daver N, Pemmaraju N, et al
    Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.
    Leuk Res. 2017;59:110-116.
    PubMed     Text format     Abstract available


  256. HERSHENFELD SA, Maki K, Rothfels L, Murray CS, et al
    Sharing post-AML consolidation supportive therapy with local centers reduces patient travel burden without compromising outcomes.
    Leuk Res. 2017;59:93-96.
    PubMed     Text format     Abstract available


  257. VALENT P, Hadzijusufovic E, Hoermann G, Fureder W, et al
    Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML.
    Leuk Res. 2017;59:47-54.
    PubMed     Text format     Abstract available


  258. LEISCH M, Weiss L, Lindlbauer N, Jungbauer C, et al
    Red blood cell alloimmunization in 184 patients with myeloid neoplasms treated with azacitidine - A retrospective single center experience.
    Leuk Res. 2017;59:12-19.
    PubMed     Text format     Abstract available


    July 2017
  259. AGGOUNE D, Sorel N, Bonnet ML, Goujon JM, et al
    Bone marrow mesenchymal stromal cell (MSC) gene profiling in chronic myeloid leukemia (CML) patients at diagnosis and in deep molecular response induced by tyrosine kinase inhibitors (TKIs).
    Leuk Res. 2017;60:94-102.
    PubMed     Text format     Abstract available


  260. MPAKOU VE, Ioannidou HD, Konsta E, Vikentiou M, et al
    Quantitative and qualitative analysis of regulatory T cells in B cell chronic lymphocytic leukemia.
    Leuk Res. 2017;60:74-81.
    PubMed     Text format     Abstract available


  261. BENICIO MTL, Ribeiro AFT, Americo AD, Furtado FM, et al
    Evaluation of the European LeukemiaNet recommendations for predicting outcomes of patients with acute myeloid leukemia treated in low- and middle-income countries (LMIC): A Brazilian experience.
    Leuk Res. 2017;60:109-114.
    PubMed     Text format     Abstract available


  262. SUKEGAWA M, Wang X, Nishioka C, Pan B, et al
    The BCR/ABL tyrosine kinase inhibitor, nilotinib, stimulates expression of IL-1beta in vascular endothelium in association with downregulation of miR-3p.
    Leuk Res. 2017;58:83-90.
    PubMed     Text format     Abstract available


  263. SZURIAN K, Csala I, Piurko V, Deak L, et al
    Quantitative miR analysis in chronic lymphocytic leukaemia/small lymphocytic lymphoma - proliferation centres are characterized by high miR-92a and miR-155 and low miR-150 expression.
    Leuk Res. 2017;58:39-42.
    PubMed     Text format     Abstract available


  264. LI D, Gale RP, Liu Y, Lei B, et al
    5'-Triphosphate siRNA targeting MDR1 reverses multi-drug resistance and activates RIG-I-induced immune-stimulatory and apoptotic effects against human myeloid leukaemia cells.
    Leuk Res. 2017;58:23-30.
    PubMed     Text format     Abstract available


    June 2017
  265. BLUM S, Martins F, Lubbert M
    Immunotherapy in adult acute leukemia.
    Leuk Res. 2017;60:63-73.
    PubMed     Text format     Abstract available


  266. ALABDULWAHAB AS, Elsayed HG, Sherisher MA, Zeeneldin A, et al
    The Dana Farber consortium protocol (DFCP) vs. classic Hyper-CVAD for treatment of acute lymphoblastic leukemia in patients <50 Y. Single institution experience.
    Leuk Res. 2017;60:58-62.
    PubMed     Text format     Abstract available


  267. KIM T, Tyndel MS, Zhang Z, Ahn J, et al
    Exome sequencing reveals DNMT3A and ASXL1 variants associate with progression of chronic myeloid leukemia after tyrosine kinase inhibitor therapy.
    Leuk Res. 2017;59:142-148.
    PubMed     Text format     Abstract available


  268. CHEN L, Guo P, Zhang Y, Li X, et al
    Autophagy is an important event for low-dose cytarabine treatment in acute myeloid leukemia cells.
    Leuk Res. 2017;60:44-52.
    PubMed     Text format     Abstract available


  269. HUANG M, Miyake K, Kagami K, Abe M, et al
    Lack of association between deletion polymorphism of BIM gene and in vitro drug sensitivity in B-cell precursor acute lymphoblastic leukemia.
    Leuk Res. 2017;60:24-30.
    PubMed     Text format     Abstract available


  270. JAIN P, Wang S, Patel KP, Sarwari N, et al
    Mast cell leukemia (MCL): Clinico-pathologic and molecular features and survival outcome.
    Leuk Res. 2017;59:105-109.
    PubMed     Text format     Abstract available


  271. VAZQUEZ-REYES A, Bobadilla-Morales L, Barba-Barba C, Macias-Salcedo G, et al
    Aneuploidy identification in pre-B acute lymphoblastic leukemia patients at diagnosis by Multiplex Ligation-dependent Probe Amplification (MLPA).
    Leuk Res. 2017;59:117-123.
    PubMed     Text format     Abstract available


  272. CHEN H, Liu KY, Xu LP, Chen YH, et al
    Haploidentical hematopoietic stem cell transplantation for pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia in the imatinib era.
    Leuk Res. 2017;59:136-141.
    PubMed     Text format     Abstract available


  273. POPP HD, Naumann N, Brendel S, Henzler T, et al
    Increase of DNA damage and alteration of the DNA damage response in myelodysplastic syndromes and acute myeloid leukemias.
    Leuk Res. 2017;57:112-118.
    PubMed     Text format     Abstract available


  274. STRUPP C, Nachtkamp K, Hildebrandt B, Giagounidis A, et al
    New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): Characteristics of refined MDS types.
    Leuk Res. 2017;57:78-84.
    PubMed     Text format     Abstract available


  275. SADRAS T, Kok CH, Perugini M, Ramshaw HS, et al
    miR-155 as a potential target of IL-3 signaling in primary AML cells.
    Leuk Res. 2017;57:57-59.
    PubMed     Text format     Abstract available


  276. HILAL T, Slone S, Peterson S, Bodine C, et al
    Cytomegalovirus reactivation is associated with a lower rate of early relapse in myeloid malignancies independent of in-vivo T cell depletion strategy.
    Leuk Res. 2017;57:37-44.
    PubMed     Text format     Abstract available


    May 2017
  277. ISHDORJ G, Kost SEF, Beiggi S, Zang Y, et al
    A novel spliced variant of the TIN2 shelterin is present in chronic lymphocytic leukemia.
    Leuk Res. 2017;59:66-74.
    PubMed     Text format     Abstract available


  278. YANG H, Fang Z, Wei Y, Bohannan ZS, et al
    Preclinical activity of FF-10501-01, a novel inosine-5'-monophosphate dehydrogenase inhibitor, in acute myeloid leukemia.
    Leuk Res. 2017;59:85-92.
    PubMed     Text format     Abstract available


  279. YAP E, Norziha ZA, Simbun A, Tumian NR, et al
    MicroRNAs that affect the Fanconi Anemia/BRCA pathway are downregulated in imatinib-resistant chronic myeloid leukemia patients without detectable BCR-ABL kinase domain mutations.
    Leuk Res. 2017;59:32-40.
    PubMed     Text format     Abstract available


  280. GU B, Wu X, Chen G, Ma X, et al
    Haploidentical allogeneic hematopoietic stem cell transplantation compared to matched unrelated transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Leuk Res. 2017;59:41-46.
    PubMed     Text format     Abstract available


  281. DUAN MH, Li H, Cai H
    A rare e13a3 (b2a3) BCR-ABL1 fusion transcript with normal karyotype in chronic myeloid leukemia: The challenges in diagnosis and monitoring minimal residual disease (MRD).
    Leuk Res. 2017;59:8-11.
    PubMed     Text format     Abstract available


  282. TAN J, Wang Y, Yu SJ, Ma YY, et al
    Prognostic factors on graft-versus-host disease-free and relapse-free survival after allogeneic hematopoietic stem cell transplantation for adults with acute leukemia.
    Leuk Res. 2017;59:1-7.
    PubMed     Text format     Abstract available


  283. STRICKLAND SA, Sun Z, Ketterling RP, Cherry AM, et al
    Independent Prognostic Significance of Monosomy 17 and Impact of Karyotype Complexity in Monosomal Karyotype/Complex Karyotype Acute Myeloid Leukemia: Results from Four ECOG-ACRIN Prospective Therapeutic Trials.
    Leuk Res. 2017;59:55-64.
    PubMed     Text format     Abstract available


  284. KUMAR B, Kalvala A, Chu S, Rosen S, et al
    Antileukemic activity and cellular effects of the antimalarial agent artesunate in acute myeloid leukemia.
    Leuk Res. 2017;59:124-135.
    PubMed     Text format     Abstract available


  285. GOPALAKRISHNAPILLAI A, Kolb EA, McCahan SM, Barwe SP, et al
    Epigenetic drug combination induces remission in mouse xenograft models of pediatric acute myeloid leukemia.
    Leuk Res. 2017;58:91-97.
    PubMed     Text format     Abstract available


  286. LYONS RM, Marek BJ, Paley C, Esposito J, et al
    Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: Registry analysis at 5 years.
    Leuk Res. 2017;56:88-95.
    PubMed     Text format     Abstract available


  287. PATEL S, Mason CC, Glenn MJ, Paxton CN, et al
    Genomic analysis of adult B-ALL identifies potential markers of shorter survival.
    Leuk Res. 2017;56:44-51.
    PubMed     Text format     Abstract available


    April 2017
  288. MEDINGER M, Zeiter D, Heim D, Halter J, et al
    Hypothyroidism following allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.
    Leuk Res. 2017;58:43-47.
    PubMed     Text format     Abstract available


  289. JASTANIAH W, Alsultan A, Al Daama S, Ballourah W, et al
    Treatment results in children with myeloid leukemia of Down syndrome in Saudi Arabia: A multicenter SAPHOS leukemia group study.
    Leuk Res. 2017;58:48-54.
    PubMed     Text format     Abstract available


  290. TIRIBELLI M, Raspadori D, Geromin A, Cavallin M, et al
    High CD200 expression is associated with poor prognosis in cytogenetically normal acute myeloid leukemia, even in FlT3-ITD-/NPM1+ patients.
    Leuk Res. 2017;58:31-38.
    PubMed     Text format     Abstract available


  291. YANG Y, Ding L, Guo ZK, Zheng XL, et al
    The epigenetically-regulated miR-34a targeting c-SRC suppresses RAF/MEK/ERK signaling pathway in K-562 cells.
    Leuk Res. 2017;55:91-96.
    PubMed     Text format     Abstract available


  292. PASIC I, Lipton JH
    Current approach to the treatment of chronic myeloid leukaemia.
    Leuk Res. 2017;55:65-78.
    PubMed     Text format     Abstract available


  293. ANNEREAU M, Willekens C, El Halabi L, Chahine C, et al
    Use of 5-azacitidine for therapy-related myeloid neoplasms in patients with concomitant active neoplastic disease.
    Leuk Res. 2017;55:58-64.
    PubMed     Text format     Abstract available


  294. CHIEN WW, Niogret C, Juge R, Lionnard L, et al
    Unexpected cross-reactivity of anti-cathepsin B antibodies leads to uncertainties regarding the mechanism of action of anti-CD20 monoclonal antibody GA101.
    Leuk Res. 2017;55:41-48.
    PubMed     Text format     Abstract available


  295. GUR HD, Wang SA, Tang Z, Hu S, et al
    Clinical significance of isolated del(7p) in myeloid neoplasms.
    Leuk Res. 2017;55:18-22.
    PubMed     Text format     Abstract available


    March 2017
  296. LI Y, Liu X, Guo X, Liu X, et al
    DNA methyltransferase 1 mediated aberrant methylation and silencing of SHP-1 gene in chronic myelogenous leukemia cells.
    Leuk Res. 2017;58:9-13.
    PubMed     Text format     Abstract available


  297. BILOUS N, Abramenko I, Saenko V, Chumak A, et al
    Clinical relevance of TP53 polymorphic genetic variations in chronic lymphocytic leukemia.
    Leuk Res. 2017;58:1-8.
    PubMed     Text format     Abstract available


  298. GARCIA C, Rosen A, Kimby E, Aguilar-Santelises M, et al
    Erratum to "Higher T-cell imbalance and growth factor receptor expression in B-cell chronic lymphocytic leukemia (B-CLL) as compared to monoclonal B-cell lymphocytosis of undetermined significance (B-MLUS)" [Leukemia Res. 13(1) (1989) 31-37].
    Leuk Res. 2017 Mar 14. pii: S0145-2126(17)30041.
    PubMed     Text format    


    February 2017
  299. GORDON MJ, Tardi P, Loriaux MM, Spurgeon SE, et al
    CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation.
    Leuk Res. 2017;53:39-49.
    PubMed     Text format     Abstract available


    December 2016
  300. LAZZAROTTO D, Candoni A, Fili C, Forghieri F, et al
    Clinical outcome of myeloid sarcoma in adult patients and effect of allogeneic stem cell transplantation. Results from a multicenter survey.
    Leuk Res. 2016;53:74-81.
    PubMed     Text format     Abstract available


  301. HEINI AD, Berger MD, Seipel K, Taleghani BM, et al
    Consolidation with autologous stem cell transplantation in first remission is safe and effective in AML patients above 65 years.
    Leuk Res. 2016;53:28-34.
    PubMed     Text format     Abstract available


    May 2016
  302. MEDINGER M, Heim D, Gerull S, Halter J, et al
    Increase of endothelial progenitor cells in acute graft-versus-host disease after allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia.
    Leuk Res. 2016;47:22-25.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: